Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/107640
Título: | Ascorbic Acid Chemosensitizes Colorectal Cancer Cells and Synergistically Inhibits Tumor Growth | Autor: | Pires, Ana S. Marques, Cláudia R. Encarnação, João C. Abrantes, Ana M. Marques, Inês A. Laranjo, Mafalda Oliveira, Rui Lopes, João E. Casalta Gonçalves, Ana C. Ribeiro, Ana B. Sarmento Botelho, Maria F. |
Palavras-chave: | ascorbic acid; chemosensitizing effect; colorectal cancer; oxaliplatin; synergy; vitamin C | Data: | 2018 | Editora: | Frontiers Media S.A. | Projeto: | PEst- C/SAU/UI3282/2013 UID/NEU/04539/2013 SFRH/BD/75300/2010 scholarship from CIMAGO to JE (Project 09/12) |
Título da revista, periódico, livro ou evento: | Frontiers in Physiology | Volume: | 9 | Número: | JUL | Resumo: | Colorectal cancer (CRC) is continuously classified as one of the most incidental and mortal types of cancer worldwide. The positive outcomes of the conventional chemotherapy are frequently associated with high toxicity, which often leads to the suspension of the treatment. Growing evidences consider the use of pharmacological concentrations of ascorbic acid (AA), better known as vitamin C, in the treatment of cancer. The use of AA in a clinical context is essentially related to the adoption of new therapeutic strategies based on combination regimens, where AA plays a chemosensitizing role. The reduced sensitivity of some tumors to chemotherapy and the highly associated adverse effects continue to be some of the major obstacles in the effective treatment of CRC. So, this paper aimed to study the potential of a new therapeutic approach against this neoplasia with diminished side effects for the patient. This approach was based on the study of the combination of high concentrations of AA with reduced concentrations of drugs conventionally used in CRC patients and eligible for first and second line chemotherapeutic regimens, namely 5-fluorouracilo (5-FU), oxaliplatin (Oxa) or irinotecan (Iri). The evaluation of the potential synergy between the compounds was first assessed in vitro in three CRC cell lines with different genetic background and later in vivo using one xenograft animal model of CRC. AA and 5-FU act synergistically in vitro just for longer incubation times, however, in vivo showed no benefit compared to 5-FU alone. In contrast to the lack of synergy seen in in vitro studies with the combination of AA with irinotecan, the animal model revealed the therapeutic potential of this combination. AA also potentiated the effect of Oxa, since a synergistic effect was demonstrated, in almost all conditions and in the three cell lines. Moreover, this combined therapy (CT) caused a stagnation of the tumor growth rate, being the most promising tested combination. Pharmacological concentrations of AA increased the efficacy of Iri and Oxa against CRC, with promising results in cell lines with more aggressive phenotypes, namely, tumors with mutant or null P53 expression and tumors resistant to chemotherapy. | URI: | https://hdl.handle.net/10316/107640 | ISSN: | 1664-042X | DOI: | 10.3389/fphys.2018.00911 | Direitos: | openAccess |
Aparece nas coleções: | I&D CIBB - Artigos em Revistas Internacionais I&D ICBR - Artigos em Revistas Internacionais FMUC Medicina - Artigos em Revistas Internacionais I&D IBILI - Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Ascorbic Acid Chemosensitizes Colorectal Cancer Cells and Synergistically Inhibits Tumor Growth.pdf | 2.97 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
115
Visto em 28/ago/2024
Downloads
63
Visto em 28/ago/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons